Purpose: Chronic myeloid leukemia (CML) can be responsive to T-cell–mediated immunity.
K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing …

Peptides from the e14a2 BCR-ABL junction will elicit T-cell responses in vitro. Here, 19
imatinib treated CML patients in first chronic phase were vaccinated with BCR-ABL peptides …

Recent studies have identified primitive, malignant stem cells which have entered the G0-
phase of the cell cycle to become'quiescent'and which are present, in small numbers, in all …

Although the emergence of bone marrow (BM)–resident p190BCR-ABL–specific T
lymphocytes has been correlated with hematologic and cytogenetic remissions in patients …

The recent successes of cancer immunotherapies have stimulated interest in the potential
widespread application of these approaches; haematological malignancies have provided …

Adult bone marrow (BM) hematopoietic stem cells (HSCs) are maintained in a quiescent
state and sustain the continuous production of all types of blood cells. HSCs reside in a …

Influenza world-wide causes significant morbidity and mortality annually, and more severe
pandemics when novel strains evolve to which humans are immunologically naïve. Because …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. With intensive
induction therapy, most patients younger than 60 years achieve complete remission …

Tyrosine kinase inhibitors (TKIs) are the current standard treatment in chronic myeloid
leukemia (CML). In addition to the BCR‐ABL target oncoprotein, they also inhibit off‐target …

This chapter summarizes the knowledge regarding the molecular biology of chronic myeloid
leukemia (CML) and the treatment modalities, including novel breakpoint cluster region‐v …